Diabetic foot infections: The role of microbiology and antibiotic treatment

Seminars in Vascular Surgery

Volumn 25, Issue 2, 2012, Pages 75-81

  Roberts, Afsoon D ^a   Simon, Gary L ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DORIPENEM; ERTAPENEM; FLUORODEOXYGLUCOSE F 18; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NAFCILLIN; OFLOXACIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TIMENTIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OSTEOMYELITIS; CONSENSUS; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC FOOT INFECTION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG TISSUE LEVEL; HOST RESISTANCE; HUMAN; INFECTION; MEDICAL SPECIALIST; MICROBIOLOGY; NEUROPATHY; NONHUMAN; OSTEOMYELITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SKIN INFECTION; SOFT TISSUE INFECTION; SURGEON; VASCULAR DISEASE; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; DIABETIC FOOT; HUMANS; OSTEOMYELITIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WOUND HEALING; WOUND INFECTION;

EID: 84864075394     PISSN: 08957967     EISSN: 15584518     Source Type: Journal    
DOI: 10.1053/j.semvascsurg.2012.04.010     Document Type: Article

References (46)

1. Boulton A.J., Vileikyte L., Ragnarson-Tennvall G., et al. The global burden of diabetic foot disease. Lancet 2005, 366(9498):1719-1724.
2. Lavery L.A., Armstrong D.G., Wunderlich R.P., et al. Risk factors for foot infections in individuals with diabetes. Diabetes Care 2006, 29:1288-1293.
3. Powlson A.S., Coll A.P. The treatment of diabetic foot infections. J Antimicrob Chemother 2010, 65(suppl 3):iii3-iii9.
4. Joshi N., Caputo G., Weitecamp M., et al. Infections in patients with diabetes. N Engl J Med 1999, 34:1906-1912.
5. Delmaire M., Maugendre D., Moreno M., et al. Impaired leukocyte functions in diabetic patients. Diabet Med 1997, 14:29-34.
6. Lipsky B.A., Berendt A.R., Deery H.G., et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004, 39:885-910.
7. Lipsky B.A. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 2004, 20(suppl 1):S68-S77.
8. Lavery L.A., Armstrong D.G., Murdoch D.P., et al. Validation of the Infectious Disease Society of America's diabetic foot infection classification system. Clin Infect Dis 2007, 44:562-565.
9. Williams D.T., Hilton J.R., Harding K.G. Diagnosing foot infections in diabetes. Clin Infect Dis 2004, 39(suppl 2):S83-S586.
10. Robson M.C., Mannari R.J., Smith P.D., et al. Maintenance of wound bacterial balance. Am J Surg 1999, 178:399-402.
11. Sotto A., Richard J.L., Jordan N., et al. Miniaturized oligonucleotide arrays. A new tool for discriminating colonization from infection due to Staphylococcus in diabetic foot ulcers. Diabetes Care 2007, 30:2051-2056.
12. Jeandrot A., Richard J.L., Combescure C., et al. Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from non-infected diabetic foot ulcers: a pilot study. Diabetologia 2008, 5. 347-342.
13. Keenan A.M., Tindel N.L., Alavi A. Diagnosis of pedal osteomyelitis in diabetic patients using current scintigraphic techniques. Arch Int Med 1989, 149:2262-2266.
14. Yuh W.T.C., Corson J.D., Baraniewski H.M., et al. Osteomyelitis of the foot in diabetic patients: evaluation with plain film, 99m Tc-MDP bone scintigraphy and MR imaging. AJR Am J Roentgenol 1989, 152:795-800.
15. Vartanians V.M., Karchmer A.W., Guirini J.M., et al. Is there a role for imaging in the management of patients with diabetic foot?. Skeletal Radiol 2009, 38:633-636.
16. Termaat M.F., Raijmakers P.G., Scholten H.J., et al. The accuracy of diagnostic imaging for the assessment of chronic osteomyelitis: a systematic review and meta-analysis. J Bone Jt Surg Am 2005, 87:2464-2471.
17. 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev 2008, 21:209-224.
18. Abdulrazak A., Bitar Z.I., Al-Shamali A.A., et al. Bacteriological study of diabetic foot infections. J Diabetes Complications 2005, 19:138-141.
19. Ramakant P., Verma A.K., Misra R., et al. Changing microbiological profile of pathogenic bacteria in diabetic foot infections: time for a rethink of which empirical therapy to choose. Diabetologia 2011, 54:58-64.
20. Miller A., Henry M. Update in diagnosis and treatment of diabetic foot infections. Phys Med Rehabil Clin N Am 2009, 20:611-625.
21. Richard J.L., Sotto A., Jourdan N., et al. Risk factors and healing impact of multi-drug resistant bacteria in diabetic foot ulcers. Diabetes Metabol 2008, 34:363-369.
22. Lipsky B.A. Osteomyelitis of the foot in the diabetic patient. Clin Infect Dis 1997, 25:1318-1326.
23. Jeffcoate W.J., Lipsky B.A., Berendt A.R., et al. Unresolved issues in the management of ulcers of the foot in diabetes. Diabet Med 2008, 25:1380-1389.
24. Crouzet J., Levigne J.P., Richard J.L., et al. Diabetic foot infections: a critical review of recent randomized clinical trials on antibiotic therapy. Int J Infect Dis 2011, 15:e601-e610.
25. Chantelau E., Tanudjaja T., Altenhofer F., et al. Antibiotic treatment for uncomplicated neuropathic foot ulcers in diabetes: a controlled trial. Diabet Med 1996, 13:156-159.
26. Kosinski M.A., Joseph W.S. Update on the treatment of diabetic foot infections. Clin Podiatr Med Surg 2007, 24:383-396.
27. Armstrong D.G., Liswood P.J., Todd W.F. 1995 William J Strickel Bronze Award. Prevalence of mixed infections in the diabetic pedal wound. A retrospective study of 112 infections. J Am Podiatr Med Assoc 1995, 85:695.
28. Lipsky B.A., Armstrong D.G., Citron D.M., et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomized, controlled, double-blinded, multicenter trial. Lancet 2005, 366:1695-1703.
29. Nannini E.C., Stryjewski M.E., Singh K.V., et al. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother 2009, 53:3437-3441.
30. Itani K.M., Eigelt L., Li J.Z. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicilin-resistant staphylococcus aureus (MRSA). Int J Antimicrob Agents 2005, 26:442-448.
31. Sharpe J.N., Shively E.H., Polk H.C. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated lower extremity skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005, 189:425-428.
32. Kutscha-Lissberg F., Hebler U., Muhr G., et al. Linezolid penetration into bone and joint tissue infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003, 47:3964-3966.
33. Rouse M.S., Piper K.E., Jacobson M., et al. Daptomycin treatment of Staphylococcal aureus experimental chronic osteomyelitis. J Antimicrob Chemother 2006, 57:301-305.
34. Traunmuller F., Schintler M.V., Metzler J., et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 2010, 65:1252-1257.
35. Kandemir O., Oztuna V., Colak M., et al. Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin resistant Staphylococcus aureus osteomyelitis model. J Chemother 2008, 20:53-57.
36. th European Congress of Clinical Microbiology and Infectious Diseases May 2009.
37. Goswami N.D., Johnson M.D., Chu V.H. Ertapenem for treatment of osteomyelitis: a case series. BMC Res Notes 2011, 4:478.
38. Pittet D., Wyssa B., Herter-Clavel C., et al. Outcomes of diabetic foot infections treated conservatively. Arch Intern Med 1999, 159:851-856.
39. Boselli E., Breith D., Djabarouti S., et al. Diffusion of ertapenem into bone and synovial tissues. J Antimicrob Chemother 2007, 60:893-896.
40. Rissing J.P. Antimicrobial therapy for chronic osteomyelitis in adults: role of quinolones. Clin Infect Dis 1997, 25:1327-1333.
41. Desplaces N., Acar J.F. New quinolones in the treatment of joint and bone infections. Rev Infect Dis 1998, 10(suppl 1):S179-S183.
42. Noel G.J., Strauss R.S., Amsler K., et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008, 52:37-44.
43. Yin L.Y., Calhoun J.H., Thomas J.K., et al. Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008, 52:1618-1622.
44. Baal J.G. Surgical treatment of the infected diabetic foot. J Clin Infect Dis 2004, 39(suppl 2):S123-S128.
45. Senneville E., Lombart A., Beltrand E., et al. Outcome of diabetic foot osteomyelitis treated non-surgically. Diabetes Care 2008, 31:637-642.
46. Hartman-Heurtier A., Senneville E. Diabetic foot osteomyelitis. Diabetes Metab 2007, 34:87-95.